Araclon Biotech partners with TFS International to advance AD vaccine ABvac40 into Phase II

TFS International and Arclon Biotech decided to continue their partnership with TFS advancing their Alzheimer’s disease vaccine ABvac40 into phase II. AD is a progressive disease associated with the accumulation, aggregation, and deposition of amyloid beta (Abeta) peptides in the brain. Abeta deposition may precede symptoms by many years. New therapies based on vaccines with active and passive immunizations against Abeta could effectively prevent Abeta deposition in the brain and, in some cases, even reverse the onset of dementia. The placebo-controlled phase II trial will be carried out at 21 clinical investigational sites across Europe over the next two years.

Ed Tumaian, Vice President Clinical Development, TFS said “After establishing such a strong partnership with Araclon during the phase I programme, we are very pleased to have been chosen to collaborate in the phase II of  this exciting and innovative new approach to the management of Alzheimer´s Disease through ABvac40 vaccine.  One of our core values at TFS is ‘It’s All About Trust,’ and we are delighted that  Araclon had the confidence to put their trust in TFS to take ABvac40 into phase II.”

ABvac40 is an innovative, active immunotherapy that uses the C-terminal fragment of the amyloid-beta 40 peptide as an immunogen.  This is a different approach to other AD vaccines, because the immunogen peptide of ABvac40 (Aβx-40) seems to be more relevant to the development of the disease than other peptides targeted by other vaccines.